Larimar Therapeutics, Inc.
LRMR
$4.36
$0.092.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 22.25M | 20.22M | 18.77M | 18.58M | 18.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 178.99M | 172.43M | 172.50M | 139.77M | 108.54M |
| Operating Income | -178.99M | -172.43M | -172.50M | -139.77M | -108.54M |
| Income Before Tax | -172.61M | -166.01M | -165.67M | -132.00M | -99.79M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -172.61 | -166.01 | -165.67 | -132.00 | -99.79 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -172.61M | -166.01M | -165.67M | -132.00M | -99.79M |
| EBIT | -178.99M | -172.43M | -172.50M | -139.77M | -108.54M |
| EBITDA | -178.68M | -172.10M | -172.15M | -139.43M | -108.21M |
| EPS Basic | -1.99 | -2.08 | -2.21 | -1.93 | -1.56 |
| Normalized Basic EPS | -1.24 | -1.30 | -1.38 | -1.20 | -0.98 |
| EPS Diluted | -1.99 | -2.08 | -2.21 | -1.93 | -1.56 |
| Normalized Diluted EPS | -1.24 | -1.30 | -1.38 | -1.20 | -0.98 |
| Average Basic Shares Outstanding | 358.15M | 317.79M | 291.50M | 270.13M | 255.61M |
| Average Diluted Shares Outstanding | 358.15M | 317.79M | 291.50M | 270.13M | 255.61M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |